Alembic Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 24	Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20

Sources of funds

Owner's fund

Equity share capital

39.31

39.31

39.31

39.31

37.70

Share application money

-

-

-

-

-

Preference share capital

-

-

-

-

-

Reserves & surplus

4,869.60

4,374.98

5,251.03

5,214.93

3,308.32

Loan funds

Secured loans

420.04

635.07

629.99

199.91

1,687.03

Unsecured loans

-

-

-

-

-

Total

5,328.95

5,049.36

5,920.33

5,454.15

5,033.05

Uses of funds

Fixed assets

Gross block

3,859.15

3,441.28

2,625.08

2,098.10

1,761.67

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

1,323.49

1,063.83

853.98

636.92

485.21

Net block

2,535.66

2,377.45

1,771.10

1,461.18

1,276.46

Capital work-in-progress

524.36

601.28

2,304.23

1,927.63

1,569.98

Investments

226.68

229.27

219.36

1,165.22

833.25

Net current assets

Current assets, loans & advances

3,111.84

2,922.42

2,779.35

2,222.15

2,199.08

Less : current liabilities & provisions

1,069.59

1,081.06

1,153.71

1,322.03

845.72

Total net current assets

2,042.25

1,841.36

1,625.64

900.12

1,353.36

Miscellaneous expenses not written

-

-

-

-

-

Total

5,328.95

5,049.36

5,920.33

5,454.15

5,033.05

Notes:

Book value of unquoted investments

226.68

229.27

219.36

978.25

833.25

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

193.55

326.18

228.15

327.06

455.59

Number of equity sharesoutstanding (Lacs)

1965.63

1965.63

1965.63

1965.63

1885.16